Performance of different data sources in identifying adverse drug events in hospitalized patients

European Journal of Clinical Pharmacology

Volumn 67, Issue 9, 2011, Pages 909-918

  Egbring, Marco ^a   Far, Elmira ^a   Knuth, Alexander ^a   Roos, Malgorzata ^b   Kirch, Wilhelm ^c   Kullak Ublick, Gerd A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Adverse drug event; Chemotherapy; Data sources; Monitoring; Oncology

Indexed keywords

CAPECITABINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; RITUXIMAB; VINCRISTINE;

ADULT; ADVERSE DRUG REACTION; ADVERSE OUTCOME; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DATA ANALYSIS; DATA EXTRACTION; DISEASE SEVERITY; DRUG FATALITY; DRUG SAFETY; DRUG USE; GASTROINTESTINAL DISEASE; GERMANY; HEMATOLOGIC DISEASE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INFECTION; KIDNEY DISEASE; LABORATORY TEST; LUNG DISEASE; MAJOR CLINICAL STUDY; MEDICAL RECORD; METABOLIC DISORDER; NEUROLOGIC DISEASE; ONCOLOGY WARD; PATIENT MONITORING; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SKIN DISEASE; UROGENITAL TRACT DISEASE;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG THERAPY; FEMALE; HOSPITALIZATION; HOSPITALS, UNIVERSITY; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; ONCOLOGY SERVICE, HOSPITAL; QUESTIONNAIRES; SWITZERLAND;

EID: 80054776669     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1020-9     Document Type: Article

References (25)

1. Ahmad SR (2003) Adverse drug event monitoring at the Food and Drug Administration. J Gen Intern Med 18(1):57-60
2. Cullen DJ et al (1995) Incident reporting system does not detect adverse drug events The: A problem for quality improvement. Jt Comm J Qual Improv 21(10):541-548
3. Olsen S et al (2007) Hospital staff should use more than one method to detect adverse events and potential adverse events: Incident reporting, pharmacist surveillance and local real-time record review may all have a place. Qual Saf Healtch Care 16 (1):40-44 (Pubitemid 46347949)
4. drug events in hospital patients. Qual Saf Health Care 14:221-226
5. Rozich JD, Haraden CR, Resar RK (2003) Adverse drug event trigger tool: A practical methodology for measuring medication related harm. Qual Saf Health Care 12(3):194-200 (Pubitemid 36723946)
6. Kvasz M et al (2000) Adverse drug reactions in hospitalized patients: A critique of a meta-analysis. MedGenMed 2(2):E3
7. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 279(15):1200-1205 (Pubitemid 28193431)
8. Fattinger K et al (2000) Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 49(2):158-167 (Pubitemid 30068294)
9. Evans RS et al (2005) Risk factors for adverse drug events: A 10-year analysis. Ann Pharmacother 39(7-8):1161-1168 (Pubitemid 40943163)
10. Rieger K et al (2004) High prevalence of unknown comedication in hospitalized patients. Eur J Clin Pharmacol 60 (5):363-368 (Pubitemid 39062323)
11. Meijerman I, Beijnen JH, Schellens JH (2006) Herb-drug interactions in oncology: Focus on mechanisms of induction. Oncologist 11(7):742-752 (Pubitemid 44157562)
12. Lapeyre-Mestre M et al (1997) Incidence and cost of adverse drug reactions in a French cancer institute. Eur J Clin Pharmacol 53 (1):19-22 (Pubitemid 27430025)
13. Lau PM, Stewart K, Dooley M (2004) The ten most common adverse drug reactions (ADRs) in patients oncology: Do they matter to you? Support Care Cancer 12(9):626-633 (Pubitemid 39280312)
14. Poole SG, Dooley MJ (2000) Establishing a baseline incidence of adverse drug reactions in hospitalized oncology patients. J Oncol Pharm Pract 6(2):55-59
15. Dooley M, Vernon J (2000) Reproducibility of treatment methodologies detailed in contemporary reports clinical trial. J Oncol Pharm Pract 6(2):50-54
16. Lyman GH (2006) Chemotherapy dose intensity and quality cancer care. Oncol Williston Park 20(9 Suppl 14):16-25
17. Classen DC et al (1997) Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 277(4):301-306 (Pubitemid 27045010)
18. Pirmohamed M et al (2004) Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. BMJ 329(7456):15-19 (Pubitemid 38869995)
19. Thomas EJ et al (1999) Costs of medical injuries in Utah and Colorado. Inquiry 36(3):255-264
20. White TJ, Arakelian A, Rho JP (1999) Counting the costs of drug-related adverse events. Pharmacoeconomics 15(5):445-458 (Pubitemid 29210948)
21. Bates DW et al (1995) Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study group. JAMA 274(1):29-34
22. Trotti A et al (2003) CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176-181 (Pubitemid 36962641)
23. Bergman U et al (1998) Drug utilization 90% -a simple method for assessing the quality of drug prescribing. Eur J Clin Pharmacol 54:113-118 (Pubitemid 28204263)
24. Weingart SN et al (2005) What can hospitalized patients tell us about adverse events? Learning from patient-reported incidents. J Gen Intern Med 20(9):830-836 (Pubitemid 41725698)
25. Basch E et al (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. Lancet Oncol 7(11):903-909 (Pubitemid 44615944)